Drug intelligence / Profile preview

vancomycin + tobramycin

Development stage: Preclinical
Lead developer: Sonoran Biosciences
Modality: Small Molecules
Administration: Ophthalmic, Irrigation, Surgical Implant

Overview

Vancomycin + tobramycin is an antibiotic combination used to treat various bacterial infections. This combination leverages the complementary antimicrobial spectrum of both drugs: vancomycin is primarily effective against gram-positive bacteria (particularly staphylococci), while tobramycin is an aminoglycoside effective against gram-negative bacteria. The combination is used in various formulations including ophthalmic preparations, bone cement impregnation for orthopedic infections, and irrigation solutions for periprosthetic joint infections.

Brand names: TobraVancFortisite
Other names: Tobra-Vanc

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on vancomycin + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vancomycin + tobramycin.

Explore the full profile